Summary
Edwards Lifesciences Corporation (EW) has released its unaudited quarterly report for the period ending September 30, 2000, marking its first reporting period as an independent entity following its spin-off from Baxter International Inc. on March 31, 2000. The company reported a net loss of $287.6 million for the nine months ended September 30, 2000, a significant swing from the $61.9 million net income reported in the same period of 1999. This loss is heavily influenced by substantial non-recurring charges, including a $291 million impairment charge related to the sale of its perfusion products business and other non-recurring charges and spin-off expenses totaling over $330 million for the nine-month period. Operationally, the company experienced a decline in net sales, with a 14.3% decrease in the third quarter and an 8.2% decrease for the nine months ended September 30, 2000, compared to the prior year. This decline was primarily attributed to changes in accounting for its Japan business, divestitures of lower-margin product lines (perfusion and mechanical cardiac assist), and shifts in the healthcare market like increased acceptance of "beating heart" surgeries. Despite these challenges, the company's gross margin percentage improved in the third quarter due to the divestitures of lower-margin products and the launch of new heart valve products.
Key Highlights
- 1Edwards Lifesciences reported a significant net loss of $287.6 million for the nine months ended September 30, 2000, compared to a net income of $61.9 million in the prior year, largely due to substantial non-recurring charges.
- 2Non-recurring charges, including a $291 million impairment related to the sale of perfusion products and other charges, totaled over $330 million for the nine-month period.
- 3Net sales decreased by 14.3% in the third quarter and 8.2% for the first nine months of 2000, driven by changes in Japan's accounting, divestitures, and market dynamics.
- 4Gross margin percentage improved in the third quarter (48.2%) compared to the prior year (46.9%) due to divestitures of lower-margin products and new product launches.
- 5The company completed the spin-off from Baxter International Inc. on March 31, 2000, and is now operating as an independent entity.
- 6Cash flow from operations was $87.5 million for the nine months ended September 30, 2000, down from $107.2 million in the prior year.
- 7The company is actively involved in litigation, including patent infringement lawsuits against Medtronic and St. Jude Medical.